ASH

ASH 2025: Multicenter review finds dexamethasone viable for CRS control in talquetamab therapy

December 12, 2025

A multicenter retrospective study of 211 patients found dexamethasone as first-line intervention for grade 1 to 2 cytokine release syndrome (CRS) achieved similar efficacy to tocilizumab, despite higher recurrence rates (50% vs. 14%), which remained low grade and manageable. Overall response rate was 77%, with no significant difference between groups. Given dexamethasone’s availability and lower cost, clinicians may consider it a feasible alternative for CRS management in talquetamab-treated patients. These results were shared at the annual American Society of Hematology meeting.

Source:

McElwee J, et al. “Dexamethasone for management of cytokine release syndrome (CRS) associated with talquetamab in patients with relapsed/refractory multiple myeloma.” Presented: 67^th American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2025; Orlando, FL. Accessed December 11, 2025. https://meetings-api.hematology.org/api/abstract/vmpreview/303272